Patent Application
20160076082
Nucleic acid assays often utilize DNA polymerase, optionally together with specific DNA probes, to generate an assay signal. For example, an assay may utilize a labelled DNA oligonucleotide as a primer for DNA polymerase. In such assays, the binding and extension of the DNA primer plays a role in assessment of assay results. An example of a potential failure mode in primer-dependent polymerase assays is the priming of DNA polymerase extension in the absence of primer hybridization. This failure can occur as a result of self priming of the DNA target molecule or amplicon or priming by other template molecules in the mix.
Provided herein are methods and compositions for preventing the 3′ ends of poly-nucleic acids from priming polymerase dependent reactions. The method comprises of adding a structure to the 3′ end of nucleic acids to prevent extension by polymerases.
In some embodiments, a method of performing a primer extension with reduced spurious priming by a primer extension product are provided. In some embodiments, the method comprises:
providing a reaction mixture comprising:
a single-stranded polynucleotide template comprising a 5′ and a 3′ end, said polynucleotide template comprising, within 6 nucleotides of the 3′ end, a double stranded stem of between 5-25 nucleotides;
a primer that anneals to a target sequence, if present, in the polynucleotide template; and
a polymerase;
exposing the reaction mixture to conditions such that the primer anneals to the target sequence, if present and the polymerase extends the primer in a template-dependent manner if the primer anneals; and
detecting the presence or amount of primer extension product.
In some embodiments, the target sequence is present in the polynucleotide template.
In some embodiments, the double stranded stem is part of a stem loop such that both strands of the double stranded stem are linked by a loop. In some embodiments, the loop comprises 1-10 nucleotides. In some embodiments, the double stranded stem comprises a 3′ terminus and the 3′ terminus of the stem is contiguous with the 3′ end of the polynucleotide template. In some embodiments, the double stranded stem comprises a 3′ terminus and linked to the 3′ terminus of the stem is 1-5 nucleotides that do not form part of the stem and that are at the 3′ end of the polynucleotide template.
In some embodiments, a first strand of the double stranded stem is formed by a nucleotide sequence in the polynucleotide template and a second strand of the stem is a separate antisense oligonucleotide complementary to the nucleotide sequence. In some embodiments, the antisense oligonucleotide is blocked from being extended by a polymerase (e.g., the oligonucleotide does not comprise a 3′-OH moiety In some embodiments, the double stranded stem comprises a 3′ terminus and the 3′ terminus of the stem is contiguous with the 3′ end of the polynucleotide template.
In some embodiments, the polynucleotide template comprises one member of a quencher/fluorescent label pair and an inhibitor oligonucleotide is annealed to the polynucleotide template downstream of the primer, wherein the inhibitor oligonucleotide comprises a second member of the quencher/fluorescent label pair such that signal from the label is quenched when the inhibitor oligonucleotide is annealed to the polynucleotide template. In some embodiments, the exposing comprises extending the primer with the polymerase, thereby displacing the inhibitor oligonucleotide and unquenching the quencher/fluorescent label pair to generate a fluorescent signal; and detecting the fluorescent signal and correlating the amount of signal to the presence or quantity of the target sequence.
In some embodiments, the polymerase is a DNA polymerase. In some embodiments, the polymerase is an RNA polymerase. In some embodiments, nucleotide triphosphates in the reaction mixture are incorporated into the primer extension product and at least some of said nucleotide triphosphates comprise a label. In some embodiments, nucleotide triphosphates comprise a fluorescent label and quencher pair such that the fluorescent label is quenched by the quencher when the nucleotide triphosphates are intact and the fluorescent label is unquenched when the nucleotide is incorporated into the primer extension product.
Also provided is a single-stranded polynucleotide comprising a 5′ and a 3′ end, said polynucleotide comprising within 6 nucleotides of the 3′ end a double stranded stem of between 5-25 nucleotides.
In some embodiments, the double stranded stem is part of a stem loop such that both strands of the double stranded stem are linked by a loop. In some embodiments, the loop comprises 1-10 nucleotides.
In some embodiments, the double stranded stem comprises a 3′ terminus and the 3′ terminus of the stem is contiguous with the 3′ end of the polynucleotide template.
In some embodiments, the double stranded stem comprises a 3′ terminus and linked to the 3′ terminus of the stem is 1-5 nucleotides that do not form part of the stem and that are at the 3′ end of the polynucleotide template.
In some embodiments, a first strand of the double stranded stem is formed by a nucleotide sequence in the polynucleotide template and a second strand of the stem is a separate anti-sense oligonucleotide complementary to the nucleotide sequence In some embodiments, the antisense oligonucleotide does not comprise a 3′-OH moiety or is otherwise blocked from being extended by a polymerase.
In some embodiments, the double stranded stem comprises a 3′ terminus and the 3′ terminus of the stem is contiguous with the 3′ end of the polynucleotide template.
In some embodiments, the polynucleotide template comprises one member of a quencher/fluorescent label pair.
In some embodiments, the single-stranded polynucleotide is between 10-5000 nucleotides long.
Also provided is a reaction mixture comprising the single-stranded polynucleotide as described above or elsewhere herein. In some embodiments, the polynucleotide comprises one member of a quencher/fluorescent label pair and the reaction mixture further comprises an inhibitor oligonucleotide, wherein the inhibitor oligonucleotide comprises a second member of the quencher/fluorescent label pair such that signal from the label is quenched when the inhibitor oligonucleotide is annealed to the polynucleotide. In some embodiments, the reaction mixture further comprises at least one of (or all of): a DNA or RNA polymerase; nucleotide triphosphates or deoxynucleotide triphosphates; a primer that anneals to a target sequence in the single-stranded polynucleotide; or an inhibitor oligonucleotide, wherein the inhibitor oligonucleotide comprises a second member of the quencher/fluorescent label pair such that signal from the label is quenched when the inhibitor oligonucleotide is annealed to the polynucleotide.
Also provided are kits comprising the single-stranded polynucleotide as described above or elsewhere herein.
Also provided is a method of making the single-stranded polynucleotide as described above or elsewhere herein. In some embodiments, the method comprises, contacting a nucleic acid sample comprising the template nucleic acid with a DNA polymerase and at least a first oligonucleotide primer to form a mixture, said first oligonucleotide primer comprising a stem loop, said primer having a 5′ end and a 3′ end and comprising from the 5′ end to the 3′ end: optionally 1-6 nucleotides at the 5′ end that do not form part of the stem loop, followed by nucleotides forming a first half of the stem of the stem loop, followed by nucleotides forming the loop of the stem loop, followed by nucleotides forming a second half of the stem that hybridizes to the first half of the stem loop, followed by a sequence at the 3′ end complementary to the template nucleic acid; and exposing the mixture to conditions such that the 3′ end of the first oligonucleotide primer anneals to the template nucleic acid and the DNA polymerase extends the 3′ end of the first oligonucleotide primer in a template-dependent manner to form a single-stranded amplicon comprising the first oligonucleotide primer and a complement of the template nucleic acid, thereby amplifying the template nucleic acid. In some embodiments, the mixture further comprises a second oligonucleotide primer comprising a sequence complementary to the single-stranded amplicon and wherein the exposing results in annealing the second oligonucleotide primer to the single-stranded amplicon and extending the second oligonucleotide primer with the DNA polymerase to form a polynucleotide that is complementary to the single-stranded amplicon and having a stem loop at the 5′ end of the polynucleotide, thereby forming a double-stranded amplicon.
In some embodiments, the second oligonucleotide primer has a 3′ and a 5′ end, and the second oligonucleotide primer comprises a stem loop ending within three nucleotides of the 5′ end of the second oligonucleotide primer.
In some embodiments, the exposing comprises the polymerase chain reaction (PCR).
In some embodiments, the first or second oligonucleotide comprises a label such that at least one strand of the double-stranded amplicon comprises the label. In some embodiments, the label is fluorescent.
In some embodiments, the first or second oligonucleotide primer comprises a quencher such that at least one strand of the double-stranded amplicon comprises the quencher.
In some embodiments, the first half and the second half of the stem each have 5-15 nucleotides. In some embodiments, between 2-6 nucleotides form the loop of the stem loop. In some embodiments, only one nucleotide at the 5′ end of the first oligonucleotide primer does not form part of the stem loop. In some embodiments, two nucleotides at the 5′ end of the first oligonucleotide primer do not form part of the stem loop.
In some embodiments, the sequence at the 3′ end of the first oligonucleotide primer and complementary to the template nucleic acid is at least 6 nucleotides long.
Also provided is an oligonucleotide primer comprising a stem loop, said primer having a 5′ end and a 3′ end and comprising from the 5′ end to the 3′ end: optionally 1-6 nucleotides at the 5′ end that do not form part of the stem loop, followed by a first half of the stem of the stem loop, followed by nucleotides forming the loop of the stem loop, followed by a second half of the stem being the reverse complement of the first half of the stem loop, followed by a sequence at the 3′ end (e.g., complementary to a template nucleic acid).
In some embodiments, the first half and the second half of the stem each have 5-15 nucleotides. In some embodiments, between 2-6 nucleotides form the loop of the stem loop. In some embodiments, only one nucleotide at the 5′ end of the first oligonucleotide primer does not form part of the stem loop. In some embodiments, two nucleotides at the 5′ end of the first oligonucleotide primer do not form part of the stem loop. In some embodiments, the sequence at the 3′ end of the first oligonucleotide primer and complementary to the template nucleic acid is at least 6 nucleotides long.
Also provided is a reaction mixture comprising the oligonucleotide primer as described above or elsewhere herein. In some embodiments, the reaction mixture further comprises one or more of: a DNA polymerase; or a second oligonucleotide having a sequence different from said oligonucleotide primer.
Also provided is kit a comprising the oligonucleotide primer as described above or elsewhere herein.
Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Generally, the nomenclature used herein and the laboratory procedures in cell culture, molecular genetics, organic chemistry, and nucleic acid chemistry and hybridization described below are those well known and commonly employed in the art. Standard techniques are used for nucleic acid and peptide synthesis. The techniques and procedures are generally performed according to conventional methods in the art and various general references (see generally, Sambrook et al. MOLECULAR CLONING: A LABORATORY MANUAL, 2d ed. (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., which is incorporated herein by reference), which are provided throughout this document. The nomenclature used herein and the laboratory procedures in analytical chemistry, and organic synthetic described below are those well known and commonly employed in the art.
The term “amplification reaction” refers to any in vitro means for multiplying the copies of a target sequence of nucleic acid. Such methods include but are not limited to polymerase chain reaction (PCR), DNA ligase chain reaction (see U.S. Pat. Nos. 4,683,195 and 4,683,202; PCR Protocols: A Guide to Methods and Applications (Innis et al., eds, 1990)), (LCR), QBeta RNA replicase, and RNA transcription-based (such as TAS and 3SR) amplification reactions as well as others known to those of skill in the art.
“Amplifying” refers to a step of submitting a solution to conditions sufficient to allow for amplification of a polynucleotide if all of the components of the reaction are intact. Components of an amplification reaction include, e.g., primers, a polynucleotide template, polymerase, nucleotides, and the like. The term “amplifying” typically refers to an “exponential” increase in target nucleic acid. However, “amplifying” as used herein can also refer to linear increases in the numbers of a select target sequence of nucleic acid, such as is obtained with cycle sequencing.
The term “amplification reaction mixture” refers to an aqueous solution comprising the various reagents used to amplify a target nucleic acid. These include enzymes, aqueous buffers, salts, amplification primers, target nucleic acid, and nucleoside triphosphates. Amplification reaction mixtures may also further include stabilizers and other additives to optimize efficiency and specificity. Depending upon the context, the mixture can be either a complete or incomplete amplification reaction mixture
“Polymerase chain reaction” or “PCR” refers to a method whereby a specific segment or subsequence of a target double-stranded DNA, is amplified in a geometric progression. PCR is well known to those of skill in the art; see, e.g., U.S. Pat. Nos. 4,683,195 and 4,683,202; and PCR Protocols: A Guide to Methods and Applications, Innis et al., eds, 1990. Exemplary PCR reaction conditions typically comprise either two or three step cycles. Two step cycles have a denaturation step followed by a hybridization/elongation step. Three step cycles comprise a denaturation step followed by a hybridization step followed by a separate elongation step.
A “primer” refers to a polynucleotide sequence that hybridizes to a sequence on a target nucleic acid and serves as a point of initiation of nucleic acid synthesis. Primers can be of a variety of lengths and are often less than 50 nucleotides in length, for example 12-30 nucleotides, in length. The length and sequences of primers for use in PCR can be designed based on principles known to those of skill in the art, see, e.g., Innis et al., supra.
A “template” refers to a polynucleotide sequence that comprises the polynucleotide to be amplified, flanked by or a pair of primer hybridization sites. Thus, a “target template” comprises the target polynucleotide sequence flanked by hybridization sites for a “forward” primer and a “reverse” primer.
As used herein, “nucleic acid” means DNA, RNA, single-stranded, double-stranded, or more highly aggregated hybridization motifs, and any chemical modifications thereof. Modifications include, but are not limited to, those providing chemical groups that incorporate additional charge, polarizability, hydrogen bonding, electrostatic interaction, points of attachment and functionality to the nucleic acid ligand bases or to the nucleic acid ligand as a whole. Such modifications include, but are not limited to, peptide nucleic acids (PNAs), phosphodiester group modifications (e.g., phosphorothioates, methylphosphonates), 2′-position sugar modifications, 5-position pyrimidine modifications, 8-position purine modifications, modifications at exocyclic amines, substitution of 4-thiouridine, substitution of 5-bromo or 5-iodo-uracil; backbone modifications, methylations, unusual base-pairing combinations such as the isobases, isocytidine and isoguanidine and the like. Nucleic acids can also include non-natural bases, such as, for example, nitroindole. Modifications can also include 3′ and 5′ modifications including but not limited to capping with a fluorophore (e.g., quantum dot) or another moiety.
The terms “polypeptide,” “peptide” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers.
A “polymerase” refers to an enzyme that performs template-directed synthesis of polynucleotides, e.g., DNA and/or RNA. The term encompasses both the full length polypeptide and a domain that has polymerase activity. DNA polymerases are well-known to those skilled in the art, including but not limited to DNA polymerases isolated or derived from Pyrococcus furiosus, Thermococcus litoralis, and Thermotoga maritime, or modified versions thereof. Additional examples of commercially available polymerase enzymes include, but are not limited to: Klenow fragment (New England Biolabs® Inc.), Taq DNA polymerase (QIAGEN), 9° N™ DNA polymerase (New England Biolabs® Inc.), Deep Vent™ DNA polymerase (New England Biolabs® Inc.), Manta DNA polymerase (Enzymatics®), Bst DNA polymerase (New England Biolabs® Inc.), and phi29 DNA polymerase (New England Biolabs® Inc.). Polymerases include both DNA-dependent polymerases and RNA-dependent polymerases such as reverse transcriptase. At least five families of DNA-dependent DNA polymerases are known, although most fall into families A, B and C. There is little or no sequence similarity among the various families. Most family A polymerases are single chain proteins that can contain multiple enzymatic functions including polymerase, 3′ to 5′ exonuclease activity and 5′ to 3′ exonuclease activity. Family B polymerases typically have a single catalytic domain with polymerase and 3′ to 5′ exonuclease activity, as well as accessory factors. Family C polymerases are typically multi-subunit proteins with polymerizing and 3′ to 5′ exonuclease activity. In E. coli, three types of DNA polymerases have been found, DNA polymerases I (family A), II (family B), and III (family C). In eukaryotic cells, three different family B polymerases, DNA polymerases α, δ, and ε, are implicated in nuclear replication, and a family A polymerase, polymerase γ, is used for mitochondrial DNA replication. Other types of DNA polymerases include phage polymerases. Similarly, RNA polymerases typically include eukaryotic RNA polymerases I, II, and III, and bacterial RNA polymerases as well as phage and viral polymerases. RNA polymerases can be DNA-dependent and RNA-dependent.
The terms “label,” “detectable label, “detectable moiety,” and like terms refer to a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means. For example, useful labels include fluorescent dyes (fluorophores), luminescent agents, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, digoxigenin, 32P and other isotopes, haptens, and proteins which can be made detectable, e.g., by incorporating a radiolabel into the peptide or used to detect antibodies specifically reactive with the peptide. The term includes combinations of single labeling agents, e.g., a combination of fluorophores that provides a unique detectable signature, e.g., at a particular wavelength or combination of wavelengths. Any method known in the art for conjugating label to a desired agent may be employed, e.g., using methods described in Hermanson, Bioconjugate Techniques 1996, Academic Press, Inc., San Diego.
A “stem loop,” also known as a “hairpin” or “hairpin loop,” refers to a secondary structure formed by a single-stranded oligonucleotide when complementary bases in a first part of the linear strand hybridize with bases in a second part of the same strand. The sequence in the second part of the sequences is the reverse complement of the first part sequence, thereby allowing for hybridization.
As used herein, the term “partitioning” or “partitioned” refers to separating a sample into a plurality of portions, or “partitions.” Partitions can be solid or fluid. In some embodiments, a partition is a solid partition, e.g., a microchannel. In some embodiments, a partition is a fluid partition, e.g., a droplet. In some embodiments, a fluid partition (e.g., a droplet) is a mixture of immiscible fluids (e.g., water and oil). In some embodiments, a fluid partition (e.g., a droplet) is an aqueous droplet that is surrounded by an immiscible carrier fluid (e.g., oil).
The presence of polymerase-extendable 3′ ends in DNA templates can increase the background noise in assays that rely on DNA-polymerase extension. The methods and compositions described herein provide a non-priming stable stem loop DNA structure or a double-stranded stem structure at the 3′ end of amplified template DNA, thereby reducing or eliminating spurious priming from the 3′ end. Template polynucleotides comprising the stem or stem loop structure at the 3′ end can then be used in primer extension reactions in which a polymerase extends the primer annealed to template polynucleotide without spurious priming events caused by the 3′ end of the template.
Also provided are various methods of advantageously using the template polynucleotides in improved primer extension methods as well as reaction mixtures and kits for their use.
As noted above, in some embodiments, a template polynucleotide is provided having a stem loop at or near the 3′ end of the polynucleotide. The inventors have tested several variants of such stem loop polynucleotides and have found that the stem loop can be contiguous with the 3′ end of the polynucleotide or there can be a few nucleotides at the 3′ end that are not part of the stem, i.e., are after the stem loop. In both embodiments, spurious 3′ priming from the 3′ end of the polynucleotide is reduced, with a greater reduction observed wherein there are a few nucleotides at the 3′ end that are not part of the stem.
Accordingly, in some embodiments, the polynucleotide can be composed of several sections:
The stem loop portion will comprise a sequence forming the first half of the stem, followed by a number of nucleotides forming the loop followed by a reverse complement of the first half of the stem. The first half and second half of the stem will generally be the exact same length though in some embodiments, one half can have one nucleotide more than the other stem half such that when the two halves anneal, one nucleotide of one half does not anneal and forms a bulge. Each half of the stem can be any size as desired, for example, between 5-15 nucleotides long, e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 nucleotides. The loop will have at least one nucleotide, and in some embodiments, between 2-6, e.g., 2, 3, 4, 5, or 6 nucleotides. In some embodiments, the stem will have a melting temperature (Tm) of at least 40, 45, 50, 55, 60, or 65° C. In some embodiments, for example, the Tm is at least 5 or 10 degrees higher than the temperature of the primer extension assay employed. The Tm of the loop can be determined empirically, and in some embodiments can be estimated, e.g., using formulas as described in F. Baldino, Jr, M.-F. Chesselet, and M. E. Lewis, Methods in Enzymology 168:766 (1989). In some embodiments, the stem has a minimum free energy (delta-G) of −8.5, −3, or less at 37° C. Ideally, the polynucleotide 3′ end sequence will allow for few or no alternative conformations (e.g., other alternative secondary structures). These aspects can be analyzed by software available to those of ordinary skill in the art. Examples of such software include the UNAFold software available at mfold.rna.albany.edu. Alternatively, more complicated (e.g., hammerhead) secondary structures can be formed so long as the structure impairs availability of the 3′ end to reduce spurious priming.
In some embodiments, the final 3′ end of the polynucleotide coincides with the 3′ terminus of the stem (i.e., the last nucleotide in the stem structure). Alternative, in some embodiments, at the 3′ end, 1, 2, 3, 4, 5 or 6 nucleotides can be present at the 5′ end that is/are not part of the stem loop due to lack of complementarity to nearby nucleotides in the 5′ direction of the stem. This aspect is illustrated, for example in the top of
The length of the polynucleotide comprising the stem loop or stem at the 3′ end can vary as needed. In some embodiments, the polynucleotide is between 10-5000, 30-5000, 30-100, 50-1000, 50-500, or 50-1000 nucleotides long.
In other embodiments, an antisense-oligonucleotide complementary to the 3′ portion, and up to the 3′ end, of the polynucleotide can be annealed to the polypeptide. This aspect is depicted, for example, in
The polynucleotides described above have reduced ability to prime polymerase extension from their 3′ end, and thus are desirably used in any method for which priming by a template polynucleotide interferes with signal of a reaction. As shown in the Example below, the template polynucleotides having an incorporated 3′ stem loop structure allow for more accurate and consistent assays that subsequently use a polymerase and that are susceptible to interference from the template 3′ end.
Accordingly, methods of using the resulting polynucleotides are also provided. For example, in some embodiments, the polynucleotide having the incorporated 3′ stem loop or stem structure is used in an inhibitor displacement reaction. An example of such a method is described in PCT Publication No. WO2012/078710. Briefly, these methods can involve a template polynucleotide having a 3′ stem or stem loop structure as described above and comprising one of a quencher/fluorescent label pair. For example the template polynucleotide can have a fluorescent label, or the template polynucleotide can have a quencher. An inhibitor polynucleotide comprising the other part of the quencher/fluorescent label pair is hybridized to the template, resulting in quenching of the fluorescent label signal by the nearby quencher. A primer targeted upstream of the annealed inhibitor polynucleotide can be used in combination with a polymerase to detect the presence or absence of a particular target sequence within the template polynucleotide. If the primer hybridizes to the template, the resulting polymerase reaction displaces the inhibitor polynucleotide, resulting in signal from the fluorescent label. In some embodiments, the primer hybridizes to a location of the single nucleotide polymorphism (SNP) under conditions in which the primer anneals if the primer is complementary to a particular SNP allele and does not anneal to an alternative SNP allele. An aspect of this method is depicted in
In another embodiment, the polynucleotide having the incorporated 3′ stem loop or stem structure is used as a template for a primer extension reaction in which the nucleotides are labeled. For example, in some embodiments, nucleotide triphosphates are linked to a fluorescent label and a quencher such that signal from the label is quenched. Incorporation of the nucleotide triphosphate into an extension product comprises incorporating a nucleotide monophosphate and release of a diphosphate. In aspects in which the quencher is linked to the diphosphate portion of the nucleotide triphosphate, incorporation of the nucleotide into the extension product results in release of the quencher thereby generating signal from the fluorescent label. Examples of nucleotides having a fluorescent label and quencher are described in, e.g., U.S. Pat. No. 7,118,871 and D. A. Berry, et al., Tetrahedron Lett, 45:2457-2461 (2004). Fluorescence can be detected and quantified as desired and optionally correlated with the quantity of original template or primer-binding target sequence on the template. Depending on the template and labeled nucleotides employed, a DNA or RNA polymerase can be used.
The methods described herein can be used to detect nucleic acid in any type of sample. In some embodiments, the sample is a biological sample. Biological samples can be obtained from any biological organism, e.g., an animal, plant, fungus, bacterial, or any other organism. In some embodiments, the biological sample is from an animal, e.g., a mammal (e.g., a human or a non-human primate, a cow, horse, pig, sheep, cat, dog, mouse, or rat), a bird (e.g., chicken), or a fish. The nucleic acid template can be RNA or DNA.
A biological sample can be any tissue or bodily fluid obtained from a biological organism, e.g., blood, a blood fraction, or a blood product (e.g., serum, plasma, platelets, red blood cells, and the like), sputum or saliva, tissue (e.g., kidney, lung, liver, heart, brain, nervous tissue, thyroid, eye, skeletal muscle, cartilage, or bone tissue), cultured cells, stool, urine, etc. In some embodiments, the sample comprises one or more cells. In some embodiments, the cells are animal cells, including but not limited to, human, or non-human, mammalian cells. Non-human mammalian cells include but are not limited to, primate cells, mouse cells, rat cells, porcine cells, and bovine cells. In some embodiments, the cells are plant or fungal (including but not limited to yeast) cells. Cells can be, for example, cultured primary cells, immortalized culture cells, or cells from a biopsy or tissue sample, optionally cultured and stimulated to divide before assayed.
In some embodiments, the template is amplified under ambient conditions (e.g., below 45 C) using a temperature sensitive DNA polymerase. In some embodiments, the primer extension reaction comprises amplifying the template nucleic acid under isothermal or thermocyclic conditions. In some embodiments, amplifying the nucleic acid molecules or regions of the nucleic acid molecule comprises polymerase chain reaction (PCR), quantitative PCR, or real-time PCR. Protocols for carrying out PCR are described, for example, in PCR Primer: A Laboratory Manual, Dieffenbach and Dveksler, eds., 2003, Cold Spring Harbor Laboratory Press; A-Z of Quantitative PCR, Bustin, ed., 2004, International University Line; Edwards, Real-Time PCR: An Essential Guide, 2004, Taylor & Francis; Real Time PCR, Dorak, ed., 2006, Taylor & Francis; PCR Protocols: A Guide to Methods and Applications, Innis, et al., eds., 1990, Academic Press, San Diego; PCR Strategies, Innis, et al., eds, 1995, Academic Press, San Diego; and PCR Applications: Protocols for Functional Genomics, Innis, et al., eds., 1999, Academic Press, San Diego.
In some embodiments, quantitative amplification (including, but not limited to, real-time PCR) methods are used for determination of the amount of nucleic acid molecules or regions of a nucleic acid molecule that co-localize in a compartment, and can be used with various controls to determine the relative amount of co-localization of nucleic acid molecules or regions of a nucleic acid molecule in a sample of interest, thereby indicating whether and to what extent nucleic acids in a sample are in close proximity to each other.
Quantitative amplification methods (e.g., quantitative PCR or quantitative linear amplification) involve amplification of nucleic acid template, directly or indirectly (e.g., determining a Ct value) determining the amount of amplified DNA, and then calculating the amount of initial template based on the number of cycles of the amplification. Amplification of a DNA locus using reactions is well known (see U.S. Pat. Nos. 4,683,195 and 4,683,202; PCR PROTOCOLS: A GUIDE TO METHODS AND APPLICATIONS (Innis et al., eds, 1990)). Typically, PCR is used to amplify DNA templates. However, alternative methods of amplification have been described and can also be employed. Methods of quantitative amplification are disclosed in, e.g., U.S. Pat. Nos. 6,180,349; 6,033,854; and 5,972,602, as well as in, e.g., Gibson et al., Genome Research 6:995-1001 (1996); DeGraves, et al., Biotechniques 34(1):106-10, 112-5 (2003); Deiman B, et al., Mol Biotechnol. 20(2):163-79 (2002). Amplifications can be monitored in “real time.”
In some embodiments, the sample or mixture comprising the template polynucleotide is partitioned into a plurality of partitions. Partitioning can be used, for example, to limit the number of copies of a template polynucleotide or other limiting reagent per partition. Partitions can include any of a number of types of partitions, including solid partitions (e.g., wells or tubes) and fluid partitions (e.g., aqueous droplets within an oil phase). In some embodiments, the partitions are droplets. In some embodiments, the partitions are microchannels. Methods and compositions for partitioning a sample are described, for example, in published patent applications WO 2010/036352, US 2010/0173394, US 2011/0092373, and US 2011/0092376, the entire content of each of which is incorporated by reference herein.
In some embodiments, the sample is partitioned into a plurality of droplets. In some embodiments, a droplet comprises an emulsion composition, i.e., a mixture of immiscible fluids (e.g., water and oil). In some embodiments, a droplet is an aqueous droplet that is surrounded by an immiscible carrier fluid (e.g., oil). In some embodiments, a droplet is an oil droplet that is surrounded by an immiscible carrier fluid (e.g., an aqueous solution). In some embodiments, the droplets described herein are relatively stable and have minimal coalescence between two or more droplets. In some embodiments, less than 0.0001%, 0.0005%, 0.001%, 0.005%, 0.01%, 0.05%, 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% of droplets generated from a sample coalesce with other droplets. The emulsions can also have limited flocculation, a process by which the dispersed phase comes out of suspension in flakes.
In some embodiments, the droplet is formed by flowing an oil phase through an aqueous sample comprising the target molecule(s) to be detected. In some embodiments, the aqueous sample comprising the target molecule(s) to be detected further comprises a buffered solution and two or more probes for detecting the target molecule(s).
The oil phase may comprise a fluorinated base oil which may additionally be stabilized by combination with a fluorinated surfactant such as a perfluorinated polyether. In some embodiments, the base oil comprises one or more of a HFE 7500, FC-40, FC-43, FC-70, or another common fluorinated oil. In some embodiments, the oil phase comprises an anionic fluorosurfactant. In some embodiments, the anionic fluorosurfactant is Ammonium Krytox (Krytox-AS), the ammonium salt of Krytox FSH, or a morpholino derivative of Krytox FSH. Krytox-AS may be present at a concentration of about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 2.0%, 3.0%, or 4.0% (w/w). In some embodiments, the concentration of Krytox-AS is about 1.8%. In some embodiments, the concentration of Krytox-AS is about 1.62%. Morpholino derivative of Krytox FSH may be present at a concentration of about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 2.0%, 3.0%, or 4.0% (w/w). In some embodiments, the concentration of morpholino derivative of Krytox FSH is about 1.8%. In some embodiments, the concentration of morpholino derivative of Krytox FSH is about 1.62%.
In some embodiments, the oil phase further comprises an additive for tuning the oil properties, such as vapor pressure, viscosity, or surface tension. Non-limiting examples include perfluorooctanol and 1H,1H,2H,2H-Perfluorodecanol. In some embodiments, 1H,1H,2H,2H-Perfluorodecanol is added to a concentration of about 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.25%, 1.50%, 1.75%, 2.0%, 2.25%, 2.5%, 2.75%, or 3.0% (w/w). In some embodiments, 1H,1H,2H,2H-Perfluorodecanol is added to a concentration of about 0.18% (w/w).
In some embodiments, the emulsion is formulated to produce highly monodisperse droplets having a liquid-like interfacial film that can be converted by heating into microcapsules having a solid-like interfacial film; such microcapsules may behave as bioreactors able to retain their contents through an incubation period. The conversion to microcapsule form may occur upon heating. For example, such conversion may occur at a temperature of greater than about 40°, 50°, 60°, 70°, 80°, 90°, or 95° C. During the heating process, a fluid or mineral oil overlay may be used to prevent evaporation. Excess continuous phase oil may or may not be removed prior to heating. The biocompatible capsules may be resistant to coalescence and/or flocculation across a wide range of thermal and mechanical processing.
Following conversion, the microcapsules may be stored at about −70°, −20°, 0°, 3°, 4°, 5°, 6°, 7°, 8°, 9°, 10°, 15°, 20°, 25°, 30°, 35°, or 40° C. In some embodiments, these capsules are useful in biomedical applications, such as stable, digitized encapsulation of macromolecules, particularly aqueous biological fluids comprising a mix of target molecules such as nucleic acids, proteins, or both together; drug and vaccine delivery; biomolecular libraries; clinical imaging applications; and others.
The microcapsule partitions may contain one or more probes or labeled primers and may resist coalescence, particularly at high temperatures. Accordingly, the capsules can be incubated at a very high density (e.g., number of partitions per unit volume). In some embodiments, greater than 100,000, 500,000, 1,000,000, 1,500,000, 2,000,000, 2,500,000, 5,000,000, or 10,000,000 partitions may be incubated per mL. In some embodiments, the sample-probe incubations occur in a single well, e.g., a well of a microtiter plate, without inter-mixing between partitions. The microcapsules may also contain other components necessary for the incubation.
In some embodiments, the sample is partitioned into at least 500 partitions, at least 1000 partitions, at least 2000 partitions, at least 3000 partitions, at least 4000 partitions, at least 5000 partitions, at least 6000 partitions, at least 7000 partitions, at least 8000 partitions, at least 10,000 partitions, at least 15,000 partitions, at least 20,000 partitions, at least 30,000 partitions, at least 40,000 partitions, at least 50,000 partitions, at least 60,000 partitions, at least 70,000 partitions, at least 80,000 partitions, at least 90,000 partitions, at least 100,000 partitions, at least 200,000 partitions, at least 300,000 partitions, at least 400,000 partitions, at least 500,000 partitions, at least 600,000 partitions, at least 700,000 partitions, at least 800,000 partitions, at least 900,000 partitions, at least 1,000,000 partitions, at least 2,000,000 partitions, at least 3,000,000 partitions, at least 4,000,000 partitions, at least 5,000,000 partitions, at least 10,000,000 partitions, at least 20,000,000 partitions, at least 30,000,000 partitions, at least 40,000,000 partitions, at least 50,000,000 partitions, at least 60,000,000 partitions, at least 70,000,000 partitions, at least 80,000,000 partitions, at least 90,000,000 partitions, at least 100,000,000 partitions, at least 150,000,000 partitions, or at least 200,000,000 partitions.
In some embodiments, the sample is partitioned into a sufficient number of partitions such that primer extension can be distinguished from random co-localization. In some embodiments, the partitioning comprises generating at least 1 partition that has 0 copies of the template molecule. In some embodiments, the partitioning comprises generating at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, or 1000 partitions or more that have 0 copies of the template molecule. In some embodiments, the partitioning comprises generating at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, or 1000 partitions or more that have 0 copies of the template molecule and at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, or 1000 partitions or more that have 1 or more copies (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more copies) of the template molecule.
In some embodiments, the sample is partitioned into a sufficient number of partitions such that at least a majority of partitions have no more than 5 copies of the template molecule (e.g., about 0.5, 1, 2, 3, 4, or 5 copies of the target molecule). In some embodiments, a majority of the partitions have no more than 5 copies of the one or more template molecules to be detected. In some embodiments, on average no more than 5 copies of the one or more template molecules are present in each partition. In some embodiments, on average about 0.5, 1, 2, 3, 4, or 5 copies of the template molecule are present in each partition. In some embodiments, on average about 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1, 2, 3, 4, or 5 probes are present in each partition.
In some embodiments, the droplets that are generated are substantially uniform in shape and/or size. For example, in some embodiments, the droplets are substantially uniform in average diameter. In some embodiments, the droplets that are generated have an average diameter of about 0.001 microns, about 0.005 microns, about 0.01 microns, about 0.05 microns, about 0.1 microns, about 0.5 microns, about 1 microns, about 5 microns, about 10 microns, about 20 microns, about 30 microns, about 40 microns, about 50 microns, about 60 microns, about 70 microns, about 80 microns, about 90 microns, about 100 microns, about 150 microns, about 200 microns, about 300 microns, about 400 microns, about 500 microns, about 600 microns, about 700 microns, about 800 microns, about 900 microns, or about 1000 microns. In some embodiments, the droplets that are generated have an average diameter of less than about 1000 microns, less than about 900 microns, less than about 800 microns, less than about 700 microns, less than about 600 microns, less than about 500 microns, less than about 400 microns, less than about 300 microns, less than about 200 microns, less than about 100 microns, less than about 50 microns, or less than about 25 microns. In some embodiments, the droplets that are generated are non-uniform in shape and/or size.
In some embodiments, the droplets that are generated are substantially uniform in volume. For example, in some embodiments, the droplets that are generated have an average volume of about 0.001 nL, about 0.005 nL, about 0.01 nL, about 0.02 nL, about 0.03 nL, about 0.04 nL, about 0.05 nL, about 0.06 nL, about 0.07 nL, about 0.08 nL, about 0.09 nL, about 0.1 nL, about 0.2 nL, about 0.3 nL, about 0.4 nL, about 0.5 nL, about 0.6 nL, about 0.7 nL, about 0.8 nL, about 0.9 nL, about 1 nL, about 1.5 nL, about 2 nL, about 2.5 nL, about 3 nL, about 3.5 nL, about 4 nL, about 4.5 nL, about 5 nL, about 5.5 nL, about 6 nL, about 6.5 nL, about 7 nL, about 7.5 nL, about 8 nL, about 8.5 nL, about 9 nL, about 9.5 nL, about 10 nL, about 11 nL, about 12 nL, about 13 nL, about 14 nL, about 15 nL, about 16 nL, about 17 nL, about 18 nL, about 19 nL, about 20 nL, about 25 nL, about 30 nL, about 35 nL, about 40 nL, about 45 nL, or about 50 nL.
Systems for performing the above methods can include, but are not limited to, those described in PCT Publication No. 2014/043388.
A digital readout assay, e.g., digital analysis, can be used to count the number of template molecules generating a primer extension by partitioning the primer extension reaction molecules and identifying the partitions containing the signal generated by the primer extension. Generally, the process of digital analysis involves determining for each partition of a sample whether the partition is positive or negative for the presence of the target sequence, template molecule, or primer extension product to be detected. For quantifying the amount of target molecule in a sample (e.g., quantifying the concentration or number of copies of a target molecule in a sample), the partitions are examined for the presence of signal associated with primer extension in each partition
In some embodiments, a detector that is capable of detecting a signal or multiple signals is used to analyze each partition for the presence or absence of the target molecule. For example, in some embodiments a two-color reader (fluorescence detector) is used. The fraction of positive-counted partitions can enable the determination of absolute concentrations for the target molecule to be measured.
Once a binary “yes-no” result has been determined for each of the partitions of the sample, the data for the partitions is analyzed using an algorithm based on Poisson statistics to quantitate the amount of target molecule in the sample. Statistical methods for quantitating the concentration or amount of a target molecule or target molecules is described, for example, in WO 2010/036352, which is incorporated by reference herein in its entirety.
Also provided are methods of generating a polynucleotide comprising a stem or stem loop structure at the 3′ end. In some embodiments, the stem-loop structure can be ligated (e.g., with DNA ligase) directly onto the 3′ end of the DNA polynucleotide of interest. In some embodiments, a transposable element (such as a DNA transposon or a retrotransposon) can be used to incorporate the stem-loop structure onto the 3′ end of a polynucleotide.
In yet other embodiments, amplification is used to incorporate a primer sequence into the polynucleotide of interest. Briefly, a stem-loop oligonucleotide can be used as a primer to copy a DNA template, incorporating the oligonucleotide into the 5′ end of the DNA molecule and then copying back with a second oligonucleotide primer. The original strand is then removed leaving behind a single stranded DNA molecule with a stem-loop at its 3′ end. This latter method is detailed more below.
In one embodiment, the structure is introduced by a PCR primer with a 5′ region containing the reverse-complement (RC) of the non-extendable-stem-loop structure. Said another way, the primer having a stem loop at the 5′ end and a 3′ end that primes DNA extension by a polymerase will generate a single-stranded amplicon, whose complementary strand will be a single-stranded DNA molecule having the reverse-complement stem loop at the 3′ end. In some embodiments, a PCR primer pair will be used for amplification of a template. In some embodiments, both primers of the primer pair will have a 5′ stem loop thereby introducing a 3′ stem loop into both strands of a PCR amplicon.
The stem loop primer(s) is composed of several sections:
At the 5′ end, the stem loop can immediately begin or optionally, 1, 2, 3, 4, 5 or 6 nucleotides can be present at the 5′ end that is not part of the stem loop.
The stem loop portion will comprise a sequence forming the first half of the stem, followed by a number of nucleotides forming the loop followed by a reverse complement of the first half of the stem. The first half and second half of the stem will generally be the exact same length though in some embodiments, one half can have one nucleotide more than the other stem half such that when the two halves anneal, one nucleotide of one half does not anneal and forms a bulge. Each half of the stem can be any size as desired, for example, between 5-15 nucleotides long, e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 nucleotides. The loop will have at least one nucleotide, and in some embodiments, between 2-6, e.g., 2, 3, 4, 5, or 6 nucleotides. The stem can have the additional criteria described above. Alternatively, more complicates secondary structures can be formed so long as the structure impairs availability of the 3′ end to reduce spurious priming.
Finally, at the 3′ end of the stem loop primer, there will be a sequence that is sufficiently complementary to a target sequence to allow for annealing of the primer to the template under the conditions used. For example, in some embodiments, the template-annealing sequence of the primer is at least 6 nucleotides long and in some embodiments, is between 10-30 nucleotides, e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides. In some embodiments, the entire template annealing region is fully complementary to the template sequence. In other embodiments, there is for example 1, 2, 3, or more nucleotides in the annealing portion that are not complementary to the template.
In practicing aspects of the present invention, many conventional techniques in molecular biology and recombinant DNA are optionally utilized. These techniques are well known and are explained in, for example, Current Protocols in Molecular Biology, 1997-2007 (F. M. Ausubel ed.), Wiley Interscience; Sambrook et al., 2001, Molecular Cloning: A Laboratory Manual, Third Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; Berger and Kimmel, Guide to Molecular Cloning Techniques Methods in Enzymology volume 152 Academic Press, Inc., San Diego, Calif. (Berger), DNA Cloning: A Practical Approach, Volumes I and II, 1985 (D. N. Glover ed.); Oligonucleotide Synthesis, 1984 (M. L. Gait ed.); Nucleic Acid Hybridization, 1985, (Hames and Higgins); Transcription and Translation, 1984 (Hames and Higgins eds.); Animal Cell Culture, 1986 (R. I. Freshney ed.); Immobilized Cells and Enzymes, 1986 (IRL Press); Perbal, 1984, A Practical Guide to Molecular Cloning; the series, Methods in Enzymology (Academic Press, Inc.); Gene Transfer Vectors for Mammalian Cells, 1987 (J. H. Miller and M. P. Calos eds., Cold Spring Harbor Laboratory); Methods in Enzymology Vol. 154 and Vol. 155 (Wu and Grossman, and Wu, eds., respectively).
In addition to methods of using the stem loop primer to generate an amplicon with at least one 3′ end comprising a step loop, reaction mixtures for performing the methods are also provided. Reaction mixtures can contain all ingredients required for generating the amplicon with one or both 3′ end of the double-stranded amplicon having a stem loop, or one or more ingredients required for completion of the reaction can be omitted. For example, in some embodiments, all ingredients required for the method are included in the reaction mixture except the template DNA sample. Thus, in some embodiments, the reaction can be prepackaged such that an end user can add a nucleic acid sample and then submit the reaction mixture to conditions to allow for primer extension. In some embodiments, the polymerase is also omitted and can be added separately by the user when the reaction method is performed.
The present invention also provides kits for use in the methods of the invention. Typically, the kit is compartmentalized for ease of use and contains containers providing components for performing the present methods.
Also provided are double-stranded DNA amplicons comprising on one or both 3′ ends a stem loop as described herein. The amplicons can be isolated from other amplification reaction materials (e.g., via gel electrophoresis or other methods) or can be part of a reaction mixture as described above.
Human genomic DNA was used as template for 23 PCR reactions. All PCR reactions contained a fluorescently labeled forward primer and one of the following reverse primers: A. a 5′-phosphate standard reverse primer, or B. a 5′-phosphate stem-loop added to the 5′ end of the reverse primer as described in
In one example of the method of the present invention, a PCR reaction has been performed using standard PCR reaction on KRAS gene, exon 2. The sequences of the reverse and forward primers used are respectively /5Phos/AAT TTA TAT TAA TTT ATT TAT TAT AAG GCC TGC TGA AAA TGA CTG AA (SEQ ID NO:1) and /56FAM/AGA TGC AGC AAT AAC ATG TGA ATG GTC CTG CAC CAG TAA TAT GCA TAT (SEQ ID NO:2). /5Phos/ and /56FAM/ correspond to 5′end phosphate and FAM modification respectively. After PCR amplification, reagents in excess are washed away using Qiagen purification kit or Agencourt AMPure XP beads. The DNA is mixed with Lambda exonuclease, buffer, dNTPs and the oligonucleotides Q, with sequence CACTGCCCACATGTTATTGCTGCATC/3IABkFQ/ (SEQ ID NO:3). /3IABkFQ/modification corresponds to the 3′end addition of a black hole quencher. Lambda exonuclease is used to turn double stranded DNA into single stranded DNA, Q is designed to be complementary to the 5′end of the amplicon and quench the fluorescence of the FAM. The mix is split in to two tubes and BST polymerase is added to one the tubes. After incubation for 30 minutes at 37 degree Celsius, the fluorescence of the solutions is measured and compared. In absence of an antisense oligonucleotide, the tube with BST has a higher fluorescence of than the one without it. This indicates that the quencher oligonucleotide does not or partially quench the amplicons when BST is added; this artifact can be explained by the looping back of the template's 3′end and further extension by BST, which displaces Q from the template. In presence of an antisense oligonucleotide complementary to the 3′ end of the target, with the sequence TCT ATA TAT TAA TTT ATT TA/3Phos/ (SEQ ID NO:4), the fluorescence of both tubes is identical; the antisense oligonucleotide competes with the self priming of the template, preventing the 3′ end of the DNA template from being extended.
The examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.
The present application claims priority to U.S. Provisional Application No. 61/816,431, filed on Apr. 26, 2013, which is incorporated by reference for all purposes.
This invention was supported, in part, by NHGRI grant number: 1R43HG005144-01. The federal government may have certain rights to this invention.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US14/35730 | 4/28/2014 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 61816431 | Apr 2013 | US |
